NTT
2.5.2022 10:02:08 CEST | Business Wire | Press release
NTT Ltd. , a global technology and business solutions provider, today announced the launch of its IoT Services for Sustainability offering. The new end-to-end stack of solutions will help businesses advance progress against global sustainability initiatives and make data-driven decisions to reduce their carbon footprint through the intelligent use of IoT connectivity.
These solutions include:
- OCR Meter Reading: An optical-based meter reader to provide near real-time data from any type of meter including water, electricity, and gas. The meter can also be used to read any type of gauge including pressure and temperature.
- Water Leak Management: This technology provides real-time, IoT enabled protection against water damage for smart spaces projects.
- Predictive Maintenance: This solution collects data from sensors to create models that predict when events of interest might occur, including potential downtime, accidents or when something might need to be replaced.
- Environmental Monitoring: This technology uses sensors to identify the presence of pollutants in the air and water as well as tracking temperature and humidity.
NTT’s IoT Services for Sustainability stack incorporates a secure IT/OT integration and end-to-end support. This helps organizations to quickly see the benefits of the technology across the entire business following deployment. Benefits include energy cost savings, faster reduction in emissions, advanced operational excellence, and better work enablement across the organization. The stack of solutions is also supported by NTT’s new LoRaWAN network, and its catalog of sensors to measure, monitor and collect data to drive sustainability objectives.
“IoT technologies are an essential tool in the global fight against climate change,” said Jeff Merritt, Head of Urban Transformation at the World Economic Forum. “We know what actions are needed to build a more sustainable future and have a robust suite of technologies available to help deliver this impact. As the world looks to accelerate the implementation of these solutions, organizations like NTT will have a critical role to play in helping companies and governments capitalize on this opportunity.”
This announcement follows the appointment of two industry veterans to drive growth and momentum across NTT’s IoT and sustainability initiatives. Wireless industry leader Devin Yaung has been appointed as SVP of Group Enterprise IoT Products and Services, NTT Ltd., bringing over 25 years of technology experience focused on business transformation. Vicky Bullivant has also been appointed as Senior Vice President, Group Sustainability, NTT Ltd. Vicky has 25 years of creating and delivering successful sustainability, social, climate and ESG strategies that underpin commercial objectives in fast-paced and evolving business environments.
"Almost two-thirds (61.4%) of CEOs say they’re aligning business strategies to the UN’s Sustainable Development Goals. Yet only 2 out of 5 businesses have the solutions needed to meet the organization's immediate objectives,” said Devin Yaung, SVP of Group Enterprise IoT Products and Services.
"Therefore, it is more critical than ever to prioritize and deliver sustainability solutions for our enterprise customers. Our new stack of solutions will help organizations reach their sustainability goals and improve operations across their business, whether it is reducing waste from manufacturing defects or understanding the carbon footprint of their supply chain. The use of IoT will empower businesses to make decisions in real-time, streamlining processes and transforming the overall sustainability of their business. We’re proud to be announcing this offering at such a critical time, and we look forward to driving change alongside our clients to create a more sustainable future."
To find out more about NTT’s IoT Services for Sustainability solutions, please visit here .
About NTT Ltd.
NTT Ltd. is a leading, global technology services company. To help our clients achieve their digital transformation goals, we use our global capabilities, expertise, and full-stack technology services delivered through our integrated services platform. As their long-term strategic partner, we help them enhance customer and employee experience, transform their cloud strategy, modernize their networks and strengthen their cybersecurity. And across their transformation priorities, we automate their business processes and IT, drawing insights and analytics from their core business data. As a global ICT provider, we employ more than 50,000 people across 57 countries, trading in 73 countries and delivering services in over 200 countries and regions. Together we enable the connected future.
Visit us at services.global.ntt
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005090/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom